We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





First-Ever COVID-19 Severity Test to Triage Patients Quickly and Accurately

By LabMedica International staff writers
Posted on 27 Nov 2020
A new test offers medical criteria of COVID-19 severity and likelihood of clinical deterioration within minutes of analyzing a blood sample, allowing healthcare practitioners to decide whether COVID-19 patients should be assigned to general wards, intensive care units (ICUs) or be discharged from the hospital.

Abionic SA (Lausanne, Switzerland) has developed the cSOFA score (Covid Sequential Organ Failure Assessment), the first-ever test that measures the likelihood of clinical deterioration in COVID-19 patients, enabling triage and assignment to the general ward or ICU upon admission and during the patients’ hospital stay. More...
A low score allows medical decisions to be made on safely discharging patients from the hospital or moving them from the ICU to the general ward, freeing up much-needed ICU and hospital capacities.

The cSOFA score is a further development from the already widespread SOFA1 score. The two scores correlate very well, although the cSOFA score is obtained much more quickly, taking only five minutes. Due to its speed, it can serve as a monitoring parameter during hospital stays in order to identify deterioration in COVID-19 patients before the presence of clear clinical signs. Using the cSOFA score, healthcare practitioners can make an informed decision on where and how to treat patients.

In order to obtain the cSOFA score, a 30 ul drop of capillary blood is sufficient. The blood sampling can be done already upon admission by a receptionist; medical training is not necessary. Within five minutes, a score is determined that serves as a base for a decision on assigning COVID-19 patients to general wards, ICUs or allowing them to recover at home. As a result of this triage, capacities in hospitals are protected and patients receive appropriate care.

The score has obtained the authorization to sell in Europe (CE mark) and relies on PSP (pancreatic stone protein), a novel biomarker that has already been clinically validated and marketed by Abionic. PSP is characterized by its diagnostic accuracy in predicting sepsis and/or multiple organ dysfunction in various types of critically ill patients. Data from 150+ COVID-19 patients from the first European wave of SARS-CoV-2 infections showed a strong link between PSP concentration and the degradation of these patients.

“COVID-19 patients may have an adverse clinical course that is not predictive and may require emergency management with transfers to intermediate and intensive care,” said Dr. François Ventura from the University Hospital of Geneva (HUG). “The cSOFA is a great tool to help predict these possible clinical deteriorations and to guide patients through the healthcare system, which is certainly very useful in these times of healthcare system overload.”

“Measuring COVID-19 severity and likelihood of clinical deterioration protects hospitals around the globe from preventable overload and makes sure patients are treated according to their needs,” said Dr. Nicolas Durand, CEO of Abionic. “Our research also indicates that modifications to the cSOFA score may be used as severity measures for other illnesses, such as flu, sepsis and other inflammatory disorders.”

Related Links:
Abionic SA


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.